Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus - Wikidata - wikimedia - TriplyDB

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

http://www.wikidata.org/entity/Q28279955

about

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases KASL clinical practice guidelines: management of hepatitis C Treating hepatitis C - what's new?Metabolic alterations and hepatitis C: From bench to bedside Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals Finally sofosbuvir: an oral anti-HCV drug with wide performance capability Natural history and clinical response: "it's the virus, stupid, or is it the host?"Antiviral treatment of hepatitis C virus infection and factors affecting efficacy Emerging concepts in immunity to hepatitis C virus infection.Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions Crystal Structure of Human Interferon-λ1 in Complex with Its High-Affinity Receptor Interferon-λR1 Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes Influence of host resistance on viral adaptation: hepatitis C virus as a case study Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.Boceprevir for untreated chronic HCV genotype 1 infection Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents Advances in the treatment of hepatitis C virus infection Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load.Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.Direct-acting antiviral agents and the path to interferon independence.The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.

P2860

Q24307721-8D952802-ACDE-4538-8608-DA9CE3605237 Q24632766-E8E04F96-2A13-49E4-8F0C-77505CC9610D Q26752471-A8926345-9E85-45CB-ABBC-B91B7647BEA8 Q26769646-B03F9689-62FB-411F-B9E7-E3413484F0AE Q26773261-1BA1F10A-CDF5-482D-8C3B-697C8FBC9ECF Q26782033-F65F8ADC-550A-469C-94F7-D9C4EA683F38 Q26822400-513A57AC-A69A-42C5-815E-939CB5FADE70 Q26824094-6267F8E0-DEEC-4732-98F7-1251AFA27592 Q26851810-ECF00E21-BD71-4A81-B472-2743533D1ECA Q27002588-ABFF1900-FF63-4697-8414-2B4DE933D892 Q27014831-95262F28-3275-47FB-9C1E-FC52D6715264 Q27664960-07CB3914-F45C-486B-8005-73F7D893BD28 Q27690772-B8890DAA-AE55-42E3-BFF4-064A834224FD Q28081216-C0949D49-F4B8-467C-BFB6-89AF45FB8A70 Q28087595-C0A29646-BEB0-43C7-98D2-7754B52B26AD Q28483964-4E407E77-D592-42E0-ACCF-F35D219DE882 Q28488762-5390C9BD-5B0D-4067-9898-E4E3E7CC8BBE Q28553721-2CE9F56D-BE94-4F87-BB8F-5E69C6531E0F Q28742764-209F7877-F65D-498E-BF1F-537D6127D9D6 Q29417108-6CCCB33B-0AE0-4FB1-B0AB-CB830CDEBF3B Q29620617-3BE335ED-465C-458A-8459-A49BD4EC196F Q30365599-C50D19B6-9831-4E52-AF9B-81163F87DEC8 Q30415138-D2AED5E5-618F-4D5F-815D-DBBA5D712A17 Q30417045-C8F9A66B-EA0E-49C4-A5AA-862F3ED42481 Q30444198-4B6CDD75-6604-4701-AB07-4D30BC032439 Q30453975-8DDA4B42-E3AC-4F38-AF09-B66A39168810 Q30583856-B47A36D2-A99A-4FC2-BCD8-1CF87BF5BFD3 Q31109635-EE72C63A-AC07-4CE1-B7AB-646521F11897 Q31115968-B73C306B-F09A-4628-9F2E-B3CF72628368 Q31153267-E2881139-BDDA-4208-9D31-393357E6F461 Q33350754-E7FAA49A-F68A-41FA-8CB4-7DFAD4CB3DA6 Q33395929-51B43356-FE93-4F73-B788-A07833C692D5 Q33408167-FD42A5CE-71A9-4F12-89E4-C14D88162D21 Q33411879-054DF9B7-C04F-45B4-8E46-10359EFEC46C Q33559298-47FEE2DB-419E-4105-8662-35D4392F244B Q33568568-CA0FDF90-0048-4DFD-84C7-98D3C4B3AB5C Q33648600-77A1AB90-08E6-4D6C-8F8F-3F563F6634E9 Q33706737-F34FCB0C-62A4-472B-ABDB-D306B3082C23 Q33727347-BD860832-6EAC-4097-826D-1512CAF8AEB8 Q33755525-4B4A9310-94B8-41EC-9537-505D70FA397B

P2860

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

http://www.wikidata.org/entity/Q28279955

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@ast

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@en

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@nl

type

label

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@ast

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@en

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@nl

prefLabel

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@ast

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@en

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@nl

P1433

Q28279955-3CF0B7EF-2F00-4E67-9370-9C510D7EA8F8

P1476

Q28279955-C7D70AB1-51C1-4902-9FA4-75F9D88085F7

P2093

Q28279955-05B1575F-9B86-46CB-A3B6-4E4C55AE124C

Q28279955-0B6EA69E-09A7-4093-A91E-B5677B1333C2

Q28279955-2396E04D-0DCE-44CA-9518-E4E0DAD7A21F

Q28279955-286F75C7-7EB5-4B23-9444-D7D1AAB4DF9A

Q28279955-37B55E12-56A3-43AD-818A-BB10386603F1

Q28279955-42B21986-6D2C-4134-8913-25CFF92F8823

Q28279955-42D548A7-6A35-4C48-8271-3375DA87BA35

Q28279955-59EA7101-D966-449F-BACF-CE0DFBD8AA49

Q28279955-5BED8E11-A9EA-4BC1-80C7-E606E05EF472

Q28279955-6F337EB6-78E4-441F-A856-DEF89CBB1F72

P304

Q28279955-28BDBA9E-760B-455C-8F61-4CD575741734

P31

Q28279955-774A33D1-9930-4458-8F1C-179EEA99A2EA

P3181

Q28279955-8AD53F45-EBFC-4EBF-A13F-82AFA9B6F033

P356

Q28279955-3270E2D5-46D7-4751-81A9-15DE6CEA1673

P407

Q28279955-0CD77810-CD81-4DEF-B058-25380D247EF4

P433

Q28279955-74CD3825-20BA-418A-91F4-6C0A80BD5B4D

P478

Q28279955-636FAFC6-AC7A-4F1C-8572-38BEEAD355D1

P50

Q28279955-07938340-E514-4F2F-86E6-29A669215021

Q28279955-0B1BA70E-7963-45BE-A3BC-BC52DE9F6680

Q28279955-0ED73A0E-2DCC-44D1-81E9-1AFFF3E03374

Q28279955-2B6F852D-9F02-479A-B7F8-AE15E805B178

Q28279955-3F64EBDF-D26A-449C-9E2C-2E94DD307EE5

Q28279955-8C849E12-4471-463F-9C39-CB09FDAF9C50

Q28279955-97EBEAF9-EB11-4157-AE3F-B5241CE5FFB7

Q28279955-E4289DE6-515F-4B63-AA58-8A8707B0C212

P577

Q28279955-274A0C2F-2414-4096-BD14-F300AED8CB1B

P698

Q28279955-8700D853-1D69-43AA-9D85-5F047F061FF9

P921

Q28279955-0e546b0f-4451-4190-82df-b40590f742a0

Q28279955-9CCADC09-1B5B-44B2-9B2C-7987626F663B

P3181

P356

J.GASTRO.2010.04.013

P1433

Gastroenterology

P1476

Interleukin-28B polymorphism i ...... n genotype 1 hepatitis C virus

@en

P2093

Alexander J Thompson

http://www.w3.org/2001/XMLSchema#string

Andrew J Muir

http://www.w3.org/2001/XMLSchema#string

Bradley Freilich

http://www.w3.org/2001/XMLSchema#string

Clifford A Brass

http://www.w3.org/2001/XMLSchema#string

David B Goldstein

http://www.w3.org/2001/XMLSchema#string

Dongliang Ge

http://www.w3.org/2001/XMLSchema#string

Eric J Lawitz

http://www.w3.org/2001/XMLSchema#string

Greg W Galler

http://www.w3.org/2001/XMLSchema#string

Hans L Tillmann

http://www.w3.org/2001/XMLSchema#string

Ira M Jacobson

http://www.w3.org/2001/XMLSchema#string

P304

120-9.e18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1986076

http://www.w3.org/2001/XMLSchema#string

P356

10.1053/J.GASTRO.2010.04.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

139

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Poynard

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20399780

http://www.w3.org/2001/XMLSchema#string

P921